Bristol-Myers Squibb Company Watch

EX-4.2

from 8-K 60 pages Bms Ireland Capital Funding Designated Activity Company, as Issuer Bristol-Myers Squibb Company, as Parent Guarantor and the Bank of New York Mellon, as Trustee First Supplemental Indenture Dated as of November 10, 2025 to Indenture Dated as of October 31, 2025 2.973% Notes Due 2030 3.363% Notes Due 2033 3.857% Notes Due 2038 4.289% Notes Due 2045 4.581% Notes Due 2055

12/34/56

EX-4.(C)

from POSASR 87 pages Bms Ireland Capital Funding Designated Activity Company Bristol-Myers Squibb Company, as Parent Guarantor and the Bank of New York Mellon, as Trustee Indenture Dated as of October 31, 2025 Debt Securities Reconciliation and Tie Between Trust Indenture Act of 1939 and Indenture*

12/34/56

EX-4.1

from 8-K 134 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, as Trustee Fifteenth Supplemental Indenture Dated as of February 22, 2024 to Indenture Dated as of June 1, 1993

12/34/56

EX-4.1

from 8-K 64 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, as Trustee Fourteenth Supplemental Indenture Dated as of November 13, 2023 to Indenture Dated as of June 1, 1993 $1,000,000,000 5.750% Notes Due 2031 $1,000,000,000 5.900% Notes Due 2033 $1,250,000,000 6.250% Notes Due 2053 $1,250,000,000 6.400% Notes Due 2063

12/34/56

EX-4.A

from 10-K 24 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

12/34/56

EX-4.1

from 8-K 62 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, as Trustee Thirteenth Supplemental Indenture Dated as of March 2, 2022 to Indenture Dated as of June 1, 1993 $1,750,000,000 2.950% Notes Due 2032 $1,250,000,000 3.550% Notes Due 2042 $2,000,000,000 3.700% Notes Due 2052 $1,000,000,000 3.900% Notes Due 2062

12/34/56

EX-4.A

from 10-K 35 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

12/34/56

EX-4.A

from 10-K 28 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

12/34/56

EX-4.1

from 8-K 87 pages Brhc10016928 Bristol-Myers Squibb Company and the Bank of New York Mellon, Trustee Twelfth Supplemental Indenture Dated as of November 13, 2020 to Indenture Dated as of June 1, 1993 $1,500,000,000 0.537% Notes Due 2023 $1,000,000,000 0.750% Notes Due 2025 $1,000,000,000 1.125% Notes Due 2027 $1,250,000,000 1.450% Notes Due 2030 $750,000,000 2.350% Notes Due 2040 $1,500,000,000 2.550% Notes Due 2050

12/34/56

EX-4.GGG

from 10-K 33 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

12/34/56

EX-4.CCC

from 10-K 59 pages Contingent Value Rights Agreement by and Between Bristol-Myers Squibb Company and Equiniti Trust Company Dated as of November 20, 2019

12/34/56

EX-4.21

from 8-K 21 pages Registration Rights Agreement

12/34/56

EX-4.1

from 8-K 312 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, Trustee Eleventh Supplemental Indenture Dated as of November 22, 2019 to Indenture Dated as of June 1, 1993

12/34/56

EX-4.2

from 8-K 6 pages Assignment, Assumption and Amendment Agreement

12/34/56

EX-4.1

from 8-K 59 pages Contingent Value Rights Agreement by and Between Bristol-Myers Squibb Company and Equiniti Trust Company Dated as of November 20, 2019

12/34/56

EX-4.1

from 8-A12B 59 pages Contingent Value Rights Agreement by and Between Bristol-Myers Squibb Company and Equiniti Trust Company Dated as of [ ], [ ]

12/34/56

EX-4.11

from 8-K 24 pages Registration Rights Agreement

12/34/56

EX-4.1

from 8-K 188 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, Trustee Tenth Supplemental Indenture Dated as of May 16, 2019 to Indenture Dated as of June 1, 1993

12/34/56

EX-4.1

from 8-K 22 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, Trustee Ninth Supplemental Indenture Dated as of February 27, 2017 to Indenture Dated as of June 1, 1993 1.600% Notes Due 2019 3.250% Notes Due 2027

12/34/56

EX-4.3

from 8-K 11 pages Bristol-Myers Squibb Company 1.750% Notes Due 2035

12/34/56